key: cord-0873474-r1sew5ce
authors: Boongird, Sarinya; Chuengsaman, Piyatida; Phanprasert, Salinnart; Kitpermkiat, Rungthiwa; Assanatham, Montira; Nongnuch, Arkom; Kiertiburanakul, Sasisopin; Malathum, Kumthorn; Phuphuakrat, Angsana; Sethaudom, Chavachol; Bruminhent, Jackrapong
title: Anti-SARS-CoV-2 Spike Protein S1 Receptor-Binding Domain Antibody to An Inactivated Whole-virus SARS-CoV-2 Vaccination in End-stage Kidney Disease Patients: An Initial Report
date: 2021-08-19
journal: Kidney Int
DOI: 10.1016/j.kint.2021.08.007
sha: a66ac697517882ad54633a1b5463d667f2f2fd94
doc_id: 873474
cord_uid: r1sew5ce

nan

Patients with end-stage kidney disease (ESKD) are at greater risk for morbidity and mortality following coronavirus disease 2019 (COVID-19) than the general population. 1 Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for this vulnerable population is the main priority to prevent COVID-19 and mitigate unfavorable or severe complications. However, the immune responses to vaccination in ESKD patients may be altered by accumulating of uremic toxins and comorbidities. 2 Currently, the effectiveness and safety profiles of immunization with SARS-CoV-2 vaccines in patients on maintenance dialysis remains poorly understood.

Several studies reported variable humoral and cellular responses to different platforms of the approved SARS-CoV-2 vaccine in chronic dialysis patients. [3] [4] [5] [6] [7] The preliminary studies revealed that most ESKD patients receiving maintenance dialysis developed decent seroconversion after the second vaccine dose. However, most immunogenicity and safety data against SARS-CoV-2 in these susceptible individuals mainly derived from the mRNA or adenoviral-vectored vaccines. Presently, these perspective profiles following immunization with an inactivated whole-virus SARS-CoV-2 vaccine among patients on maintenance dialysis have not been evaluated.

A pilot, multi-center, prospective study of ESKD patients on maintenance dialysis received a two-dose immunization, administered at a 4-week interval, of an inactivated whole-virus SARS-CoV-2 vaccine CoronaVac ® (Sinovac Biotech Ltd., China) was conducted from April 2021 to July 2021. SARS-CoV-2-specific humoral immunogenicity was measured at baseline before administering the vaccine, four weeks after the first dose, and two weeks after the second dose, 

Outcomes of patients with end-stage kidney disease hospitalized with COVID-19

Vaccination in chronic kidney disease

Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients

Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: a call to arms

Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won

Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients

Humoral response of the mRNA-1273 SARS-CoV-2 vaccine in peritoneal dialysis patients